3D Printing in Solid Dosage Forms and Organ-on-Chip Applications

Kassem, Tarek; Sarkar, Tanoy; Nguyen, Trieu; Saha, Dipongkor; Ahsan, Fakhrul

doi:10.3390/bios12040186

Cited by 15 publications

(6 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• articles investigating the environmental impacts of additive manufacturing/3D printing technology when directly related to pharmaceutical dosing. These technologies are used to tailor drug-dosage and forms based on genomic or other molecular data specific to patients (82,83).…”

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Environmental impacts associated with the manufacturing of personalised medicines: a scoping review

Al-Jarshawi¹,

Lucassen²,

Samuel³

2023

Preprint

View full text Add to dashboard Cite

This report presents the findings of a project funded by UCL’s Future Targeted Healthcare Manufacturing Hub. This Hub aims to explore the challenges associated with manufacturing personalised medicines. Personalised medicines aim to move therapies from population-based, “one-size-fits-all” approaches (medicines designed for use by a population) to stratified approaches (medicines targeted to specific sub-populations based on particular (e.g., molecular/genetic) characteristics), and ultimately to approaches whereby therapeutic interventions are tailored to the specific molecular characteristics of one individual. This move has implications for medicines manufacturing processes. These processes have typically relied on forecasted demand, but as medicines become increasingly targeted to an individual’s characteristics, manufacturing approaches need to change. For example, for therapeutic interventions tailored to one individual, the manufacturing process has to wait until the individual’s molecular profile has been determined so that this information can be incorporated into therapeutic production. Other aspects of personalised medicine–such as the use of wearable sensors and 3D printing to customise medication dosages–may also require different approaches to manufacturing. The economic, social, and environmental aspects of any innovation are a necessary component of decision-making about implementation and use. This is the premise of sustainable development. In this report, we aim to better understand how the adverse environmental costs associated with personalised medicines manufacturing are being considered in the academic literature.

show abstract

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Environmental impacts associated with the manufacturing of personalised medicines: a scoping review

Al-Jarshawi¹,

Lucassen²,

Samuel³

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The printable materials used are biocompatible and biodegradable; 3d printed dosage form can be fabricated using a computer-generated model and printer filled with drug-polymer solutions or supplied with filament to design the pill, printlet with precise and complex geometries that would be impossible to create using traditional manufacturing tools. Recent past, FDA approved 3D printed dosage form for the delivery of an anti-epileptic drug, spritam [40]. PVA filament-based 3D printing refers to a 3D printing process where a PVA (polyvinyl alcohol) filament is used as the printing material.…”

Section: Of 21mentioning

confidence: 99%

Development and Characterization of Chitosan-Based Spray-Dried Solid Dispersions of Apigenin: 3D Printed Shell-Pill for Improved Efficacy of Model Flavonoid

Alali¹,

Ahmed²,

Fatima³

et al. 2023

Preprint

View full text Add to dashboard Cite

This study aimed to develop chitosan-based apigenin spray dried solid dispersion using 1:1,1:1.5,1:2 w/w ratios. The results of process yield and drug assay were found to be (87.5%, 94.2%, and 95.86%), (95.2 ±1.34%), (99.5 ±0.85%), and (97.6 ±2.42%), respectively, for AC1, AC2, and AC3. Flow properties indicate the free flow of powders. FTIR revealed compatibility among chitosan and apigenin, and DSC and XRD showed prepared solid dispersion was on a molecular level and available in amorphous. In contrast, SEM images reflect irregular block and near-spherical shape elongated particles in the selected AC2. The antimicrobial examination reflects that AC2 was more effective against Gram-positive, negative, and fungal strains. AC2 SDSDs has more anti-oxidant property compared to pure flavonoid (AGN). Anti-proliferative activity against A549 lung cancer cell lines showed better anti-cancer activity by AC2 SDSDs. The selected AC2 SDSD filled in a 3D shell pill and further characterized for 3D shell pill for dissolution profiles and stability studies. The product has sustained release and similar release profiles after three months of storage. The findings suggest that the AC2 SDSDs may be a promising candidate for further development as a 3D printed drug delivery system for treating multiple disease conditions using model flavonoid- apigenin.

show abstract

“…Three-dimensional printing, which can create fine features with lower costs, has some limitations such as low z-resolution, absence of extremely smooth surface finish, limited restricted diversity of transparent materials, and low precision of fabricated hollow and void sections [ 152 ]. Various technologies are associated with three-dimensional printing to develop organ-on-chip applications [ 153 ]. This section covers four microfluidics fabrication approaches associated with three-dimensional printing: fused deposition modeling, vat polymerization, multi-jet printing, and two-photon polymerization.…”

Section: Fabrication Of Microfluidic Devicesmentioning

confidence: 99%

Biomedical Applications of Microfluidic Devices: A Review

et al. 2022

View full text Add to dashboard Cite

Both passive and active microfluidic chips are used in many biomedical and chemical applications to support fluid mixing, particle manipulations, and signal detection. Passive microfluidic devices are geometry-dependent, and their uses are rather limited. Active microfluidic devices include sensors or detectors that transduce chemical, biological, and physical changes into electrical or optical signals. Also, they are transduction devices that detect biological and chemical changes in biomedical applications, and they are highly versatile microfluidic tools for disease diagnosis and organ modeling. This review provides a comprehensive overview of the significant advances that have been made in the development of microfluidics devices. We will discuss the function of microfluidic devices as micromixers or as sorters of cells and substances (e.g., microfiltration, flow or displacement, and trapping). Microfluidic devices are fabricated using a range of techniques, including molding, etching, three-dimensional printing, and nanofabrication. Their broad utility lies in the detection of diagnostic biomarkers and organ-on-chip approaches that permit disease modeling in cancer, as well as uses in neurological, cardiovascular, hepatic, and pulmonary diseases. Biosensor applications allow for point-of-care testing, using assays based on enzymes, nanozymes, antibodies, or nucleic acids (DNA or RNA). An anticipated development in the field includes the optimization of techniques for the fabrication of microfluidic devices using biocompatible materials. These developments will increase biomedical versatility, reduce diagnostic costs, and accelerate diagnosis time of microfluidics technology.

show abstract

3D Printing in Solid Dosage Forms and Organ-on-Chip Applications

Cited by 15 publications

References 82 publications

Environmental impacts associated with the manufacturing of personalised medicines: a scoping review

Environmental impacts associated with the manufacturing of personalised medicines: a scoping review

Development and Characterization of Chitosan-Based Spray-Dried Solid Dispersions of Apigenin: 3D Printed Shell-Pill for Improved Efficacy of Model Flavonoid

Biomedical Applications of Microfluidic Devices: A Review

Contact Info

Product

Resources

About